As biotech companies navigate increasingly complex pathways from scientific discovery to commercial success, the importance of location, expertise, and ecosystem has never been greater. In this exclusive conversation with BioPharma BoardRoom, Kirsten... Read more
As healthcare systems around the world grapple with rising costs, growing chronic disease burdens, and increasing demand for innovative therapies, biosimilars are emerging as a powerful solution to improve both affordability and access. In this exclu... Read more
As precision medicine continues to reshape cancer care, ensuring equitable access to genomic testing remains a critical priority. New research presented at ISPOR 2026 highlights how the adoption of homologous recombination repair (HRR) genetic testin... Read more
As artificial intelligence becomes increasingly embedded in healthcare research, the ability to generate reliable, transparent, and regulatory-grade evidence is taking on new significance. At ISPOR 2026, discussions around the future of real-world ev... Read more
Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more
Financial performance Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US. Q1 2026 adjusted sales, excluding the 340B provision reversal, decreased... Read more
AGC Biologics, your friendly CDMO expert, was selected by Teikoku Seiyaku Co., Ltd., a leader in transdermal drug delivery, to provide microbial contract development and manufacturing services for KTP-001, a recombinant human matrix metalloproteina... Read more
LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic ... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
